SCHEMBL14720320

SCHEMBL14720320

CC(=O)OCC(Br)c1ccc(Br)cc1F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APLNR P35414 4/20 0.41
DGAT1 O75907 1/20 0.38
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
AAK1 Q2M2I8 1/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CCR1 P32246 1/20 0.34
CCR2 P41597 1/20 0.34
ACACB O00763 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
FPR2 P25090 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720436 0.80 TDP1 (0.35) DGAT1ALDH1A1L3MBTL1AAK1MAPT
SCHEMBL9515508 0.75 APLNR (0.48) APLNRDGAT1ALDH1A1L3MBTL1GAA
SCHEMBL14720356 0.75 APLNR (0.42) APLNRDGAT1ALDH1A1MAPTFPR2
SCHEMBL19914018 0.74 DGAT1 (0.44) APLNRDGAT1ALDH1A1L3MBTL1GAA
SCHEMBL27900437 0.74 CYP1A2 (0.46) ALDH1A1MAPT
SCHEMBL14720336 0.74 APLNR (0.47) APLNRDGAT1ALDH1A1L3MBTL1AAK1
SCHEMBL28948407 0.72 APLNR (0.46) APLNRDGAT1ALDH1A1L3MBTL1AAK1
SCHEMBL13034145 0.72 MEN1 (0.53) DGAT1ALDH1A1MAPT
SCHEMBL31192692 0.72 APLNR (0.42) APLNRDGAT1ALDH1A1MAPT
SCHEMBL1679175 0.71 PTGS1 (0.51) APLNRDGAT1PTGS1PTGS2FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 APLNR 907/4885DGAT1 93/4885ALDH1A1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.